Archive | March, 2018

RESI Toronto Innovation Challenge Finalists Announced

29 Mar

By Cole Bunn, Director of Research, LSN

cole-wp

We are excited to showcase the top 30 RESI Innovation Challenge startup applicants, who will be taking part in the poster presentation showcase at the third annual RESI conference held in Toronto, as a part of the Toronto Health Innovation Week. These handpicked companies represent the key sectors of the healthcare space including therapeutics, medical devices, diagnostics and digital health, and were selected based on their scientific/technical merit and commercial viability.

The Innovation Challenge companies will compete for each attendee’s RESI Cash tokens throughout the day, which serves as a vote of their potential. The top 3 companies will win additional RESI tickets to events of their choosing and a feature in the LSN newsletter (20,000 readership), giving them access to hundreds of additional investors and ultimately enhancing their likelihood of securing an investment. Make sure to visit the exhibition hall to meet the RESI innovators and “invest” in your favorites!

Therapeutics

MedTech Device

Diagnostics

Digital Health

RESI on MaRS Panel Announcement: Venture Philanthropy

29 Mar

By James Huang, Research Analyst, LSN

james-wp

RESI endeavors to bring a diverse pool of investors to each of our events for early stage life science companies. Among them are venture philanthropic foundations whose profound expertise within their targeted disease areas makes them great resources for any entrepreneur looking to work within their areas of expertise. Additionally, venture philanthropic investors tend to focus on assets at an earlier stage than typical VCs, with the aim of helping new treatments traverse the infamous “Valley of Death.”

LSN is pleased to announce a panel of five venture philanthropic investors for the upcoming RESI on MaRS this April 10th in Toronto. In this panel, these investors will explain their unique strategies and expertise, and entrepreneurs can learn how to find and work with a venture philanthropy investor in their domain. RESI attendees will have the exclusive opportunity to hear from:

RESI on MaRS Panel Announcement: Diagnostics Investors

29 Mar

By Claire Jeong, Research Analyst, LSN

claire

The field of diagnostics can be a difficult space to navigate due to challenges in the regulatory and reimbursement processes that hinder successful commercialization. However, the implications of diagnostic technologies can be enormous; from precision genomics that enable optimum health management and personalized care to novel biomarkers that can successfully detect high mortality diseases in its earliest stages, diagnostics companies are developing some of the most highly disruptive technologies in the industry.

In this session, we invite 5 investors with strong expertise in this diverse space to speak about their unique approaches in working with early-stage companies. Investors will discuss the types of investment opportunities they seek and share valuable insights on building long lasting relationships, differentiating your technology from similar competitors, and more. We hope you will be able to join us for the RESI Toronto Conference in the MaRS Innovation Center on April 10th to meet these awesome panelists!

Moderated by Drew Taylor, Lead Medical Researcher, Epic Capital Management, the panel participants are:

  • Yiu-Lian Fong, Innovation Lead for Diagnostics, Johnson & Johnson (Medical Devices)
  • Kelly Holman, Co-Founder & Managing Director, Genesys Capital
  • Yvan Côté, General Manager of Dynacare Next & Orchid PRO-DNA, Dynacare
  • Amine Benmoussa, Principal (Healthcare), BDC Healthcare Fund

 

Hot Investor Mandate 1: France-Based VC Initially Invests Up to $15M in Eary-Stage Therapeutics and Medical Device Companies

29 Mar

A venture capital firm based in Paris, France invests in early stage life science companies and seeks to be the first institutional investor in a company. The firm has raised numerous funds to date and currently has approximately €1.4 billion AUM. The firm is currently investing from its recent fund of €300M. The firm makes seed and venture investments, oftentimes investing in a company’s seed round and later leading the Company’s A round. The firm can allocate €1-15M initially and up to € 30 M over the life of the investment.

The firm is currently looking for biotech therapeutics and medical devices and tends to steer away from service companies. For therapeutics, the firm is agnostic in terms of subsector and invests in small molecule, biologics, cell and gene therapy, etc. The firm is also indication agnostic, but currently most interested in oncology (especially CAR-T assets), immunology/inflammation, CNS/neurology (with a particular interest in rare neuro conditions). The firm will consider products as early as 24-months from IND through to Phase III. For medical devices, the firm seeks paradigm-shifting technologies that can reach a human proof-of-concept stage in a relatively short period of time, and prefers PMA regulatory pathways although is open to other regulatory pathways as well.

The firm prefers to lead or co-lead an investment and generally requires a board seat in its portfolio companies. The firm seeks outstanding entrepreneurial management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Strategic Venture Fund of a Japanese Pharma Seeks to Invest in First-In-Class Therapeutics Opportunities, with Strong Focus in Oncology

29 Mar

A strategic corporate venture capital fund by a full-fledged oncology pharmaceutical company headquartered in Tokyo, Japan, seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the pharmaceutical’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy, on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the pharmaceutical’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: PE Firm with Offices in North America Invests & Provides Advisory Support to Medical and Surgical Devices and Healthcare IT Companies

29 Mar

A private equity firm founded in 2014 with offices in USA and Canada manages a fund that provides equity and equity-like investments in high growth companies in healthcare technology verticals. The size of investments generally fall under the range of $2-5 M per company, and the firm seeks to make 2-3 investments per year.

The firm works closely with clients of the firm’s advisory arm that provides companies with financial, strategic, and growth consulting and transaction advisory services including M&A. The firm will also help companies through regulatory approvals and developing new strategic and financial partnerships. The firm will consider companies that are outside of this network, but it is important that these companies form a close long-term relationship with the firm in leveraging their development. This integrated network provides for superior insight and strategy of lower risk. The firm looks globally with a strong focus in North America.

The firm is interested in highly innovative medical and surgical device companies, healthcare IT, healthcare services. The firm will not consider products in pharma or biotech industries. Medical device products should be patented and on the cusp of FDA clearance. The firm will support all classes of medical devices including 510k and PMA regulatory pathways. Healthcare IT companies are expected to demonstrate market traction prior to investment.

The firm seeks to work with companies with an experienced, motivated management team. The firm can act as the lead investor in all financing rounds, and requires a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Global Organization Provides Seed Capital to Early-Stage Healthcare Technologies Applicable to Emerging Markets

29 Mar

A global charity organization with an established footprint in over 100 countries worldwide, dedicated to tackling the problem of poverty and injustice, has launched a new initiative through its Canada operations. In 2016, the organization built an investment team to support entrepreneurs developing innovative technologies for emerging markets. Currently, this is the organization’s only operation with an investment vehicle.
The organization seeks to invest up to $250K in early-stage social innovations. In addition to providing capital, the organization will take an active role in helping entrepreneurs with growing their companies and providing valuable connections through their global reach.

The organization will consider any early-stage technology in the healthcare sectors that can help address and solve problems in emerging countries, with a high potential for social impact.

The organization does not have specific management team requirements, but prior experience in working with or developing technologies for emerging countries is a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.